BACKGROUND: Bone metastases are responsible for most of the morbidity associated with hormone-refractory prostate cancer (HRPC). 153Sm-ethylenediaminetetramethylene phosphonate (153Sm-EDTMP) has been approved for palliation of painful skeletal metastases. We retrospectively investigated the possible synergistic effect on survival of 153Sm-EDTMP (given to HRPC patients for bone pain palliation) and chemotherapy. METHODS: Forty-five HRPC patients were evaluated, with a median age of 71 years. The number of metastatic bone sites was <or=10 in 25 patients and >10 in 20 patients. Median serum PSA was 224 ng/ml. Bone pain was mild in 6 patients, moderate in 16, severe in 22 and intolerable in 1. Fifteen patients were only treated with 153Sm-EDTMP (group A), while 30 patients also received chemotherapy (estramustine phosphate or mitoxantrone plus prednisone) at variable times: between 3 and 5 months after 153Sm-EDTMP (14 patients, group B) or within 1 month after 153Sm-EDTMP (16 patients, group C). RESULTS: Haematological toxicities observed after either regimen were in general mild, consistent with common observations after either 153Sm-EDTMP or chemotherapy, and without any additive adverse effects in the patients receiving both 153Sm-EDTMP and chemotherapy. Bone pain palliation to some degree was induced by 153Sm-EDTMP in 32/45 patients (71.1%), the proportion of patients with a favourable clinical response being significantly higher in group C than in group A (87.5% vs 53.3%, p = 0.0388). Also in terms of biochemical response (serum PSA levels), patients of group C performed significantly better than patients of group A (p = 0.0235). Overall median survival from the time of administration of 153Sm-EDTMP was 15 months in the total cohort of 45 patients, and was significantly longer in group C than in either group B (30 months vs 11 months, p = 0.023) or group A (30 months vs 10 months, p = 0.008). CONCLUSION: The results of this study confirm that 153Sm-EDTMP is effective in terms of pain relief and PSA response, with minimal toxicity. When it was administered in combination with chemotherapy, prolonged survival indicated actual clinical benefit, while there were no additive toxicities. These results provide the rationale for future prospective evaluation of combined therapeutic strategies.
BACKGROUND: Bone metastases are responsible for most of the morbidity associated with hormone-refractory prostate cancer (HRPC). 153Sm-ethylenediaminetetramethylene phosphonate (153Sm-EDTMP) has been approved for palliation of painful skeletal metastases. We retrospectively investigated the possible synergistic effect on survival of 153Sm-EDTMP (given to HRPC patients for bone pain palliation) and chemotherapy. METHODS: Forty-five HRPC patients were evaluated, with a median age of 71 years. The number of metastatic bone sites was <or=10 in 25 patients and >10 in 20 patients. Median serum PSA was 224 ng/ml. Bone pain was mild in 6 patients, moderate in 16, severe in 22 and intolerable in 1. Fifteen patients were only treated with 153Sm-EDTMP (group A), while 30 patients also received chemotherapy (estramustine phosphate or mitoxantrone plus prednisone) at variable times: between 3 and 5 months after 153Sm-EDTMP (14 patients, group B) or within 1 month after 153Sm-EDTMP (16 patients, group C). RESULTS: Haematological toxicities observed after either regimen were in general mild, consistent with common observations after either 153Sm-EDTMP or chemotherapy, and without any additive adverse effects in the patients receiving both 153Sm-EDTMP and chemotherapy. Bone pain palliation to some degree was induced by 153Sm-EDTMP in 32/45 patients (71.1%), the proportion of patients with a favourable clinical response being significantly higher in group C than in group A (87.5% vs 53.3%, p = 0.0388). Also in terms of biochemical response (serum PSA levels), patients of group C performed significantly better than patients of group A (p = 0.0235). Overall median survival from the time of administration of 153Sm-EDTMP was 15 months in the total cohort of 45 patients, and was significantly longer in group C than in either group B (30 months vs 11 months, p = 0.023) or group A (30 months vs 10 months, p = 0.008). CONCLUSION: The results of this study confirm that 153Sm-EDTMP is effective in terms of pain relief and PSA response, with minimal toxicity. When it was administered in combination with chemotherapy, prolonged survival indicated actual clinical benefit, while there were no additive toxicities. These results provide the rationale for future prospective evaluation of combined therapeutic strategies.
Authors: A N Serafini; S J Houston; I Resche; D P Quick; F M Grund; P J Ell; A Bertrand; F R Ahmann; E Orihuela; R H Reid; R A Lerski; B D Collier; J H McKillop; G L Purnell; A P Pecking; F D Thomas; K A Harrison Journal: J Clin Oncol Date: 1998-04 Impact factor: 44.544
Authors: Wallace Akerley; James Butera; Terek Wehbe; Richard Noto; Barry Stein; Howard Safran; Frank Cummings; Sundaresan Sambandam; John Maynard; Gregory Di Rienzo; Louis Leone Journal: Cancer Date: 2002-03-15 Impact factor: 6.860
Authors: P Sabbatini; S M Larson; A Kremer; Z F Zhang; M Sun; H Yeung; M Imbriaco; I Horak; M Conolly; C Ding; P Ouyang; W K Kelly; H I Scher Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: Lance C Pagliaro; Ebrahim S Delpassand; Dallas Williams; Randall E Millikan; Shi-Ming Tu; Christopher J Logothetis Journal: Cancer Date: 2003-06-15 Impact factor: 6.860
Authors: Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun Journal: CA Cancer J Clin Date: 2003 Jan-Feb Impact factor: 508.702
Authors: Jianqing Lin; Victoria J Sinibaldi; Michael A Carducci; Samuel Denmeade; Danny Song; Theodore Deweese; Mario A Eisenberger Journal: Urol Oncol Date: 2009-12-04 Impact factor: 3.498
Authors: Mala Chakraborty; Elizabeth K Wansley; Jorge A Carrasquillo; Sarah Yu; Chang H Paik; Kevin Camphausen; Michael D Becker; William F Goeckeler; Jeffrey Schlom; James W Hodge Journal: Clin Cancer Res Date: 2008-07-01 Impact factor: 12.531
Authors: Marnix G E H Lam; Tjitske B Bosma; Peter P van Rijk; Bernard A Zonnenberg Journal: Eur J Nucl Med Mol Imaging Date: 2009-03-25 Impact factor: 9.236
Authors: Marnix G E H Lam; Amel Dahmane; Wil H M Stevens; Peter P van Rijk; John M H de Klerk; Bernard A Zonnenberg Journal: Eur J Nucl Med Mol Imaging Date: 2007-12-22 Impact factor: 9.236